128 related articles for article (PubMed ID: 19308409)
1. Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn.
Israyelyan A; Shannon EJ; Baghian A; Kearney MT; Kousoulas KG
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1201-10. PubMed ID: 19308409
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.
Israyelyan A; Chouljenko VN; Baghian A; David AT; Kearney MT; Kousoulas KG
Virol J; 2008 Jun; 5():68. PubMed ID: 18518998
[TBL] [Abstract][Full Text] [Related]
3. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide delayed the ability of 4T1 cells to amass into tumors in Balb/c mice.
Israyelyan A; Sandoval F; Baghian A; Kearney MT; Shannon EJ
Immunopharmacol Immunotoxicol; 2012 Jun; 34(3):408-12. PubMed ID: 21942927
[TBL] [Abstract][Full Text] [Related]
6. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma.
Ogawa F; Takaoka H; Iwai S; Aota K; Yura Y
Anticancer Res; 2008; 28(6A):3637-45. PubMed ID: 19189645
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice.
Maria de Souza C; Fonseca de Carvalho L; da Silva Vieira T; Cândida Araújo E Silva A; Teresa Paz Lopes M; Alves Neves Diniz Ferreira M; Passos Andrade S; Dantas Cassali G
Biomed Pharmacother; 2012 Oct; 66(7):491-8. PubMed ID: 22705333
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.
Shibata MA; Morimoto J; Shibata E; Otsuki Y
Cancer Gene Ther; 2008 Dec; 15(12):776-86. PubMed ID: 18654613
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Ganesh S; Gonzalez-Edick M; Gibbons D; Ge Y; VanRoey M; Robinson M; Jooss K
Cancer Gene Ther; 2009 May; 16(5):383-92. PubMed ID: 19011598
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
14. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
15. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.
Varghese S; Rabkin SD; Nielsen PG; Wang W; Martuza RL
Clin Cancer Res; 2006 May; 12(9):2919-27. PubMed ID: 16675589
[TBL] [Abstract][Full Text] [Related]
16. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells.
Sobotkova E; Duskova M; Eckschlager T; Vonka V
Int J Oncol; 2008 Aug; 33(2):421-6. PubMed ID: 18636165
[TBL] [Abstract][Full Text] [Related]
18. Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice.
Li J; Dong X; Xu Z; Jiang X; Jiang H; Krissansen GW; Sun X
J Biomed Sci; 2008 Jan; 15(1):99-109. PubMed ID: 17705027
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor and antimetastatic activities of plasmid pcDNA3. 1-IP10 complexed with cationic liposome in mice with 4T1 breast cancer].
Tang QQ; Shi W; Lü HM; Peng XC; Wen YJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):195-8. PubMed ID: 19462888
[TBL] [Abstract][Full Text] [Related]
20. [The therapeutic effect of HSV1-hGM-CSF combined with doxorubicin on the mouse breast cancer model].
Zhuang XF; Zhang SR; Liu BL; Wu JL; Li XQ; Gu HG; Shu Y
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):178-185. PubMed ID: 29575835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
